U.S. markets closed

Synthetic Biologics, Inc. (SYN)

NYSE American - NYSE American Delayed Price. Currency in USD
Add to watchlist
0.5194+0.0155 (+3.08%)
At close: 4:00PM EDT

0.5000 -0.02 (-3.74%)
After hours: 7:35PM EDT

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Engulfing Line (Bullish)

Engulfing Line (Bullish)

Previous Close0.5039
Open0.5043
Bid0.4900 x 3000
Ask0.5194 x 3000
Day's Range0.4910 - 0.5194
52 Week Range0.2500 - 0.7500
Volume301,854
Avg. Volume751,014
Market Cap10.097M
Beta (5Y Monthly)1.99
PE Ratio (TTM)N/A
EPS (TTM)-0.8770
Earnings DateAug 06, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.38
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Synthetic Biologics Announces Submission of IND Application to U.S. FDA for SYN-020 Intestinal Alkaline Phosphatase
    PR Newswire

    Synthetic Biologics Announces Submission of IND Application to U.S. FDA for SYN-020 Intestinal Alkaline Phosphatase

    Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal ("GI") diseases in areas of high unmet need, today announced that it submitted an Investigational New Drug ("IND") application with the U.S. Food and Drug Administration ("FDA") for its SYN-020 Intestinal Alkaline Phosphatase ("IAP") program. The IND application supports an initial indication of SYN-020 for the treatment of radiation enteropathy secondary to pelvic cancer therapy. Under the IND application, the Company intends to conduct a Phase 1 single ascending dose study in healthy volunteers, designed to evaluate SYN-020 for safety, tolerability, and pharmacokinetic parameters.

  • Thomson Reuters StreetEvents

    Edited Transcript of SYN.A earnings conference call or presentation 5-May-20 8:30pm GMT

    Q1 2020 Synthetic Biologics Inc Earnings Call

  • Synthetic Biologics Enters into Exclusive Option to License Intellectual Property for Use of SYN-020 to Treat and Prevent Age-Related Metabolic and Inflammatory Diseases
    PR Newswire

    Synthetic Biologics Enters into Exclusive Option to License Intellectual Property for Use of SYN-020 to Treat and Prevent Age-Related Metabolic and Inflammatory Diseases

    Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal ("GI") diseases in areas of high unmet need, today announced that it entered into an agreement with Massachusetts General Hospital ("MGH") granting the Company an option for an exclusive license to intellectual property and technology related to the use of intestinal alkaline phosphatase ("IAP") to maintain GI and microbiome health, diminish systemic inflammation, and treat age-related diseases. If executed, the Company plans to use this license in the advancement of an expanded clinical development program for SYN-020, the Company's proprietary recombinant version of bovine IAP currently in pre-clinical development.